Client of a consultant lobbyist
Life Sciences Ontario
- Meetings this Parliament
- 0
- With MPs
- 0
- Since Nov 2021
- 4
- Active registrations
- 0
Most recent reported meeting: Oct 30, 2024.
Lobbying by Life Sciences Ontario: its registrations, its lobbyists, the bills it has named and every meeting it has reported with federal office holders since November 2021.
← LobbyingRegistrations in effect
Life Sciences Ontario has no active registration. Organizations must register once paid lobbying passes the legal threshold, and their registration ends when it stops.
Reported meetings
Spreadsheet-
Reported by Stephanie Levee · Consultant
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
Engagement with officials regarding Health Canada’s proposed development of a strategy for drugs for rare disorders and other aspects of national pharmacare, including proposals for a Canada Drug Agency and a national formulary. Read more
Canada’s Innovation and Skills Plan, led by Innovation, Science and Economic Development Canada, with respect to ensuring that the life sciences sector is a major focus of the government’s post-COVID recovery plan.
Health Canada Regulations Amending the Patented Medicines Regulations (Additional Factors and Information Reporting Requirements) (SOR/2019-298) published in the Canada Gazette Part 2 on August 21, 2019.
Engagement with federal officials regarding Innovation, Science and Economic Development Canada’s plans for the creation of new biomanufacturing capacity for Canada.
Guidelines, policies and programs related to regulatory and reporting functions of the Patented Medicine Prices Review Board
-
Reported by Stephanie Levee · Consultant
- Michelle Boudreau · Executive Director, Health Canada (HC)
- Daniel MacDonald · Director General, Health Canada (HC)
- Samir Khan · Director, Health Canada (HC)
Engagement with federal officials regarding Innovation, Science and Economic Development Canada’s plans for the creation of new biomanufacturing capacity for Canada. Read more
Engagement with officials regarding Health Canada’s proposed development of a strategy for drugs for rare disorders and other aspects of national pharmacare, including proposals for a Canada Drug Agency and a national formulary.
Health Canada Regulations Amending the Patented Medicines Regulations (Additional Factors and Information Reporting Requirements) (SOR/2019-298) published in the Canada Gazette Part 2 on August 21, 2019.
Canada’s Innovation and Skills Plan, led by Innovation, Science and Economic Development Canada, with respect to ensuring that the life sciences sector is a major focus of the government’s post-COVID recovery plan.
Guidelines, policies and programs related to regulatory and reporting functions of the Patented Medicine Prices Review Board
-
Reported by Stephanie Levee · Consultant
- Michelle Boudreau · Executive Director, Health Canada (HC)
- Samir Khan · Director, Health Canada (HC)
Economic DevelopmentHealthIndustryIntellectual PropertyInternational TradeRegional DevelopmentResearch and DevelopmentScience and Technology
-
Reported by Stephanie Levee · Consultant
- Jean-Sebastien Bock · Director of Policy, Health Canada (HC)
- Sandenga Yeba · Senior Policy Advisor, Health Canada (HC)
Economic DevelopmentHealthIndustryIntellectual PropertyInternational TradeRegional DevelopmentResearch and DevelopmentScience and Technology
From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.